A phase II study of M6620 and irinotecan in TP53 mutant gastric and gastroesophageal junction (GEJ) adenocarcinoma patients (pts) INCT036413131.

被引：0
|
作者：
Das, Satya
Whisenant, Jennifer
Doyle, Austin
Allegra, Carmen Joseph
Berlin, Jordan
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] NCI, Rockville, MD USA
[3] NSABP Fdn, Gainesville, FL USA
[4] Univ Florida, Gainesville, FL USA
[5] Vanderbilt Univ, Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.TPS175
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS175
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results.
    Pinto, C.
    Di Fabio, F.
    Siena, S.
    Cascinu, S.
    Llimpe, F. L. Rojas
    Ceccarelli, C.
    Mutri, V.
    Giaquinta, S.
    Piana, E.
    Martoni, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 186S - 186S
  • [32] A phase II trial of the Src kinase inhibitor AZD0530 in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A trial of the PMH phase II consortium
    Mackay, H.
    Au, H.
    McWhirter, E.
    Alcindor, T.
    Jarvi, A.
    MacAlpine, K.
    Wang, L.
    Wright, J. J.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study)
    Pinto, C.
    Di Fabio, F.
    Barone, C.
    Siena, S.
    Falcone, A.
    Llimpe, F. L. Rojas
    Cascinu, S.
    Giaquinta, S.
    Schinzari, G.
    Mutri, V.
    Martoni, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] A phase II study of perioperative mFOLFOX chemotherapy plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ), and stomach
    Sun, Weijing
    Saeed, Anwaar
    Al-Rajabi, Raed Moh'd Taiseer
    Kasi, Anup
    Veeramachaneni, Nirmal K.
    Al-Kasspooles, Mazin Mazin
    Baranda, Joaquina Celebre
    Phadnis, Milind
    Godwin, Andrew K.
    Olyaee, Mojtaba
    Madan, Rashna
    Nagji, Alykhan
    Williamson, Stephen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [35] A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach.
    Sun, Weijing
    Saeed, Anwaar
    Mohd, Raed
    Al-Rajabi, Taiseer
    Kasi, Anup
    Veeramachaneni, Nirmal K.
    Al-Kasspooles, Mazin Francis
    Baranda, Joaquina Celebre
    Phadnis, Milind A.
    Godwin, Andrew K.
    Olyaee, Mojtaba
    Madan, Rashna
    Streeter, Natalie
    Nagji, Alykhan
    Williamson, Stephen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li, Ning
    Li, Zhi
    Fu, Qiang
    Zhang, Bin
    Zhang, Jian
    Wan, XiangBin
    Lu, Chaomin
    Wang, Jinbang
    Deng, Wenying
    Wei, Chen
    Ma, Yijie
    Bie, Liangyu
    Wang, Mengyu
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [37] A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
    Shah, Manish A.
    Power, Derek G.
    Kindler, Hedy L.
    Holen, Kyle D.
    Kemeny, Margaret M.
    Ilson, David H.
    Tang, Laura
    Capanu, Marinela
    Wright, John J.
    Kelsen, David P.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (06) : 1475 - 1481
  • [38] A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
    Manish A. Shah
    Derek G. Power
    Hedy L. Kindler
    Kyle D. Holen
    Margaret M. Kemeny
    David H. Ilson
    Laura Tang
    Marinela Capanu
    John J. Wright
    David P. Kelsen
    Investigational New Drugs, 2011, 29 : 1475 - 1481
  • [39] Positron emission tomography (18FDG-PET) in targeted therapy with cetuximab in gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian phase II study
    Di Fabio, F.
    Pinto, C.
    Fanti, S.
    Rojas, Llimpe F.
    Longobardi, C.
    Nanni, C.
    Funaioli, C.
    Ambrosini, V
    Sperandi, F.
    Martoni, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 92 - 92
  • [40] Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
    Becerra, Carlos
    Stephenson, Joe
    Jonker, Derek J.
    Cohn, Allen Lee
    Asmis, Timothy R.
    Bekaii-Saab, Tanios S.
    Conkling, Paul R.
    Garbo, Lawrence E.
    Lenz, Heinz-Josef
    Richards, Donald A.
    Spira, Alexander I.
    Mikhail, Sameh
    Goodwin, Rachel Anne
    Yoon, Harry H.
    Hume, Stephanie
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345